Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal

Amgen shares fell 5% after hours after Novartis' phase III Lp(a)HORIZON trial of pelacarsen failed its primary endpoint in 8,323 cardiovascular-disease patients. Although pelacarsen substantially reduced lipoprotein(a) levels, it did not lower the composite risk of cardiovascular death, heart attack, stroke or urgent coronary revascularization versus placebo. The result raises read-through risk for Amgen's phase III olpasiran program, with investors now focused on whether Lp(a) lowering can demonstrate cardiovascular-outcomes benefits.

Analysis

This is a target-validation shock rather than merely a single-asset failure: biomarker reduction without outcomes benefit forces investors to reassess the probability that Lp(a) is a modifiable causal driver in secondary prevention. The key unresolved distinction is whether the result reflects insufficient magnitude/duration of lowering, trial-population selection, or a genuinely non-actionable target; until disclosed subgroup and absolute-event-rate data answer that question, cross-program valuation should incorporate a materially higher probability of failure.

AMGN’s siRNA modality may still differentiate through deeper and more durable suppression, but that is not equivalent to clinical differentiation. Its pipeline value should be discounted now because the remaining proof point is a long-duration, event-driven readout rather than a near-term commercial launch; after a strong prior run, the market can compress the embedded cardiovascular-franchise premium over the next 1-3 months. The more direct economic exposure is likely IONS, where a failed partnered asset reduces expected milestones and royalty optionality, while NVS’s diversified earnings base should absorb the setback more easily.

The contrarian case is that this trial may have selected patients whose residual event risk is dominated by inflammation, diabetes, or irreversible plaque burden, making late intervention ineffective despite Lp(a) lowering. If detailed data show benefit among the highest baseline-Lp(a) cohort or with sustained deep reductions, AMGN, LLY and SLN could rebound sharply as investors reframe the issue as dose, duration and patient-selection rather than target invalidation. Falsification for the bearish field view would be a statistically persuasive exposure-response or high-Lp(a) subgroup signal, not simply another demonstration of biomarker lowering.

Key Decisions for Investors

• Reduce or hedge AMGN overweight exposure over the next several sessions; retain only a smaller core position pending peer-reviewed trial details. The risk/reward is unfavorable if the stock still carries meaningful olpasiran terminal-value assumptions, while upside requires evidence not yet available from the competitor study.
• Express relative exposure with long NVS / short IONS over a 1-3 month horizon, sized modestly: NVS has limited asset-level earnings sensitivity, whereas IONS faces a more concentrated loss of partner economics and a weaker platform-validation narrative. Exit if disclosed economics show immaterial pelacarsen milestone/royalty contribution to IONS or if subgroup data revive the program's commercial rationale.
• Do not initiate long AMGN calls or broad Lp(a)-platform longs solely on the after-hours decline. Set an event alert for full endpoint-component, baseline-Lp(a), achieved-Lp(a), and subgroup disclosure; a benefit concentrated in extreme-Lp(a) patients would support selectively revisiting AMGN and LLY, while uniformly null data would justify further pipeline-value cuts.
• For biotech books with Lp(a) exposure, trim high-beta small-cap platform risk first, including SLN, rather than treating the selloff as indiscriminate value. Re-enter only after management clarifies whether competing phase III protocols enrich for materially higher baseline Lp(a), use longer exposure, or target a different risk population.